Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Closed to Accrual

Canadian Cancer Trials Group IND.196 - A Phase I/II Study of Foretinib in Patients with Previously Treated Non-Small Cell Lung Cancer Receiving Standard Erlotinib Therapy - was closed to accrual on January 24, 2013 having met the phase I study objectives.

Following review of the clinical data (dose limiting toxicities, required dose modifications) and PK results from 31 patients treated at 3 dose levels, dose level 2 (30 mg foretinib, 150 mg erlotinib) was determined to be the recommended phase II dose (RP2D).

A study design change in 2011 eliminated the phase II portion of this trial.

Thanks goes to participating centres, staff and patients for participating in this trial.